SCHEMBL1821047

SCHEMBL1821047

Cc1ccc(C(C(=O)O)C(=O)O)cc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.61
ALDH1A1 P00352 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
LMNA P02545 3/20 0.46
CES2 O00748 2/20 0.44
CES1 P23141 2/20 0.44
ACHE P22303 1/20 0.44
ALOX5 P09917 1/20 0.44
CYP2C19 P33261 1/20 0.43
POLB P06746 1/20 0.43
SRD5A2 P31213 1/20 0.43
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
KEAP1 Q14145 1/20 0.41
NFE2L2 Q16236 1/20 0.41
CHRNA7 P36544 1/20 0.41
AKR1C3 P42330 2/20 0.41
FFAR1 O14842 1/20 0.41
AKR1C2 P52895 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21269213 0.98 SRC (0.58) SRCALDH1A1SMN1; SMN2LMNACES2
SCHEMBL28314445 0.98 SRC (0.58) SRCALDH1A1SMN1; SMN2LMNACES2
SCHEMBL28314627 0.98 SRC (0.58) SRCALDH1A1SMN1; SMN2LMNACES2
SCHEMBL21269292 0.98 SRC (0.58) SRCALDH1A1SMN1; SMN2LMNACES2
SCHEMBL21268958 0.98 SRC (0.58) SRCALDH1A1SMN1; SMN2LMNACES2
SCHEMBL28316200 0.98 SRC (0.58) SRCALDH1A1SMN1; SMN2LMNACES2
SCHEMBL28314388 0.95 SRC (0.56) SRCALDH1A1SMN1; SMN2LMNACES2
SCHEMBL2427033 0.89 SRC (0.48) SRCALDH1A1SMN1; SMN2LMNACES2
SCHEMBL11212242 0.89 LMNA (0.50) SRCALDH1A1SMN1; SMN2LMNACES2
SCHEMBL11212236 0.87 SRC (0.46) SRCALDH1A1SMN1; SMN2LMNACES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070219194-A1 Conjugate which inhibits SH2 domains from binding with phosphoproteins for use in prevention and/or treatment of cancer, diabetes, obesity, autoimmune, inflammatory, metabolic and/or cardiovascular diseases; pharmacokinetics, bioavailability GEORGETOWN UNIVERSITY (US) 2007-09-20 US claimed
EP-1163262-A1 PHENYLALANINE DERIVATIVES THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2001-12-19 EP claimed
WO-2000056760-A1 PHENYLALANINE DERIVATIVES THE UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2000-09-28 WO claimed
CN-114981081-B Multilayer container, method for producing the same, and method for producing recycled polyester 三菱瓦斯化学株式会社 2025-03-04 CN disclosed
CN-119365507-A Polyurethane foam 井上株式会社 2025-01-24 CN disclosed
WO-2023248535-A1 POLYURETHANE FOAM 株式会社イノアックコーポレーション 2023-12-28 WO disclosed
WO-2023248536-A1 POLYURETHANE FOAM 株式会社イノアックコーポレーション 2023-12-28 WO disclosed
CN-115397919-B Antistatic agent for thermoplastic resin 三洋化成工业株式会社 2023-08-22 CN disclosed
CN-116261509-A Single-layer container, method for producing same, and method for producing recycled polyester 三菱瓦斯化学株式会社 2023-06-13 CN disclosed
CN-113165251-B Multilayer container and method for manufacturing the same 三菱瓦斯化学株式会社 2023-06-13 CN disclosed
CN-115243891-A Multilayer container, method for producing same, and method for producing recycled polyester 三菱瓦斯化学株式会社 2022-10-25 CN disclosed
EP-0658548-A1 Benzenesulfonamide derivative and process for preparing thereof TANABE SEIYAKU CO., LTD. (JP) 1995-06-21 EP disclosed
EP-0355017-B1 Method for producing a block copolyamide MITSUBISHI CHEM IND (JP) 1994-06-15 EP disclosed
EP-0510526-A1 Use of sulfonamides as drug and new sulfonamides F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) 1992-10-28 EP disclosed
US-5011893-A Condensation polymerization of dimerized fatty acids, diamines and lactams MITSUBISHI KASEI CORPORATION (JP) 1991-04-30 US disclosed
EP-0355017-A2 Method for producing a block copolyamide Mitsubishi Chemical Corporation (JP) 1990-02-21 EP disclosed
US-4892921-A LIQUID CRYSTAL POLYMERS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) 1990-01-09 US disclosed
US-4835246-A Pendant benzazole rigid-rod aromatic heterocyclic polymer THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) 1989-05-30 US disclosed
US-4785115-A INTERMEDIATES FOR HETEROCYCLIC POLYMERS OF COMPRESSIVE STRENGTH THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE UNITED STATES (US) 1988-11-15 US disclosed
US-3988326-A Process for N-acylation of 7 amino cephem compounds MEIJI SEIKA KAISHA, LTD. (JA) 1976-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219194-A1 Conjugate which inhibits SH2 domains from binding with phosphoproteins for use in prevention and/or treatment of cancer, diabetes, obesity, autoimmune, inflammatory, metabolic and/or cardiovascular diseases; pharmacokinetics, bioavailability TYRO3, PTMS, ACP1 SRC 7/4885ALDH1A1 3894/4885SMN1; SMN2 4607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.